Evidence map›Paper›PMID 41861091›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

ETV4 Promotes Colorectal Cancer Progression by Reprogramming Asparagine Metabolism to Remodel the Stromal Microenvironment.

Dujiang Fu, Meijia Zhang, Maoping Cai, Miao Wang, Ziao Huang, Zesheng Lin, Yixin Liu, Wang Qian, Guopeng Chen, Yuxing Liang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Dujiang FuDepartment of Radiation and Medical Oncology, Hubei Cancer Clinical Study Center & Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, China.ORCID https://orcid.org/0009-0006-8727-1146
Meijia ZhangDepartment of Radiation and Medical Oncology, Hubei Cancer Clinical Study Center & Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, China.
Maoping CaiDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Miao WangDepartment of Radiotherapy, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan, Kunming, China.
Ziao HuangDepartment of Radiation and Medical Oncology, Hubei Cancer Clinical Study Center & Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, China.
Zesheng LinDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yixin LiuDepartment of Radiation and Medical Oncology, Hubei Cancer Clinical Study Center & Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, China.
Wang QianDepartment of Radiation and Medical Oncology, Hubei Cancer Clinical Study Center & Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, China.
Guopeng ChenDepartment of Radiation and Medical Oncology, Hubei Cancer Clinical Study Center & Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, China.
Yuxing LiangDepartment of Radiation and Medical Oncology, Hubei Cancer Clinical Study Center & Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, China.
Dongyi WeiDepartment of Radiation and Medical Oncology, Hubei Cancer Clinical Study Center & Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, China.
Jing XieDepartment of Radiation and Medical Oncology, Hubei Cancer Clinical Study Center & Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, China.
Picheng YanDepartment of Radiation and Medical Oncology, Hubei Cancer Clinical Study Center & Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, China.
Yuanyuan QuDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yongchang WeiDepartment of Radiation and Medical Oncology, Hubei Cancer Clinical Study Center & Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, China.ORCID https://orcid.org/0000-0001-7205-4663

Funding

Chen Xiao-Ping Foundation for the Development of Science and Technology of Hubei Province CXPJJH122006-1014Innovation Platform Support Project of Zhongnan Hospital, Wuhan University PTXM2025006National Natural Science Foundation of China 12331018
6 · The paper itself

Abstract

Colorectal cancer (CRC) lethality is largely driven by liver metastasis and the associated tumor microenvironment (TME). This study identifies ETS variant transcription factor 4 (ETV4) as a central integrator of oncogenic signaling, metabolism, and stromal remodeling. In CRC cells, hepatocyte growth factor (HGF)/MET signaling induces ETV4 via an ERK1/2-p65 pathway. ETV4, in turn, directly activates MET and asparagine synthetase (ASNS), creating a positive feedback loop that amplifies MET signaling and elevates intracellular asparagine (Asn). Tumor-derived Asn acts as a paracrine signal that induces inflammatory cancer-associated fibroblast (iCAF) like activation in hepatic stellate cells (HSCs) and promotes iCAF polarization in primary CAFs, leading to enhanced HGF secretion that further stimulates MET

Indexed as

Adenovirus E1A ProteinsAsparagineColorectal NeoplasmsProto-Oncogene Proteins c-etsTumor MicroenvironmentAnimalsCell Line, TumorDisease ProgressionHepatocyte Growth FactorHumansMetabolic ReprogrammingMiceProto-Oncogene Proteins c-metSignal TransductionAdenovirus E1A ProteinsAsparagineETV4 protein, humanHepatocyte Growth FactorProto-Oncogene Proteins c-etsProto-Oncogene Proteins c-metasparagine metabolismcolorectal cancerETV4HGF/MET signalingstromal microenvironment

Identifiers

PMID41861091
PMCPMC13159137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.